CYP 2 C 19 inhibitor in suspended human hepatocytes

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions

  2018cited by this paper
• Human hepatocytes and cytochrome P450‐selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s

  2018cited by this paper
• Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model

  2017cited by this paper
• Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective

  2016influential reference
• Development of novel tools for the in vitro investigation of drug-induced liver injury

  2015cited by this paper
• Root mean square error (RMSE) or mean absolute error (MAE)

  2014cited by this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013influential reference
• Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy

  2013influential reference
• CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects

  2013cited by this paper
• Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions

  2013cited by this paper
• A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes.

  2012influential reference
• Antiepileptic Drug Interactions: A Clinical Guide

  2012cited by this paper
• Pharmacokinetic Drug Interactions Between Clobazam and Drugs Metabolized by Cytochrome P450 Isoenzymes

  2012cited by this paper
• The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors

  2011cited by this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011influential reference
• CYP2C19 Inhibition: The Impact of Substrate Probe Selection on in Vitro Inhibition Profiles

  2008cited by this paper
• Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance

  2007cited by this paper
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data

  2005cited by this paper
• Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.

  2004influential reference
• An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

  2003cited by this paper
• (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.

  2002influential reference
• CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects

  2001cited by this paper
• Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation.

  2001cited by this paper
• Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

  1997influential reference
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997cited by this paper
• Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S‐mephenytoin 4′‐hydroxylation phenotype and genotype *

  1997cited by this paper
• Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics

  1992cited by this paper

• Drug clearance by aldehyde oxidase: can we avoid clinical failure?

  2022cites this paper